RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia

doi:10.1038/s41569-024-01034-w

Comment

. 2024 Jun;21(6):353.

doi: 10.1038/s41569-024-01034-w.

RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia

Karina Huynh¹

Affiliations

PMID: 38654089
DOI: 10.1038/s41569-024-01034-w

Comment

RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia

Karina Huynh. Nat Rev Cardiol. 2024 Jun.

. 2024 Jun;21(6):353.

doi: 10.1038/s41569-024-01034-w.

Author

Karina Huynh¹

Affiliation

¹ Nature Reviews Cardiology, . nrcardio@nature.com.

PMID: 38654089
DOI: 10.1038/s41569-024-01034-w

No abstract available

PubMed Disclaimer

Comment on

Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial.
Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, San Martin J, Hellawell J, Ballantyne CM. Gaudet D, et al. JAMA Cardiol. 2024 Jul 1;9(7):620-630. doi: 10.1001/jamacardio.2024.0959. JAMA Cardiol. 2024. PMID: 38583092 Free PMC article. Clinical Trial.
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, Soran H, Prohaska TA, Xia S, Ginsberg HN, Witztum JL, Tsimikas S; Balance Investigators. Stroes ESG, et al. N Engl J Med. 2024 May 16;390(19):1781-1792. doi: 10.1056/NEJMoa2400201. Epub 2024 Apr 7. N Engl J Med. 2024. PMID: 38587247 Clinical Trial.
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, Murphy SA, Goodrich EL, Zhang S, Gaudet D, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano RP, Sabatine MS; Bridge–TIMI 73a Investigators. Bergmark BA, et al. N Engl J Med. 2024 May 16;390(19):1770-1780. doi: 10.1056/NEJMoa2402309. Epub 2024 Apr 7. N Engl J Med. 2024. PMID: 38587249 Clinical Trial.

Cited by

Prediction of Interspecies Translation for Targeting Delivery Coefficients of GalNAc-siRNA Silencing Apolipoprotein C-III Using a Mechanistic Minimal Physiologically Based Pharmacokinetic/Pharmacodynamic Model.
Tian Z, Luo H, Chu Y, Liu Y, Gao S, Song L, Yang Z, Liu D. Tian Z, et al. Clin Pharmacokinet. 2025 Jun;64(6):865-883. doi: 10.1007/s40262-025-01513-4. Epub 2025 May 3. Clin Pharmacokinet. 2025. PMID: 40317426

References

Original articles

1. Bergmark, B. A. et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2402309 (2024) - DOI - PubMed
1. Stroes, E. S. G. et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2400201 (2024) - DOI - PubMed
1. Gaudet, D. et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2024.0959 (2024) - DOI - PubMed

1. Brandts, J. & Ray, K. K. et al. Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Nat. Rev. Cardiol. 20, 600–616 (2023) - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Bergmark, B. A. et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2402309 (2024) - DOI - PubMed

[2] Bergmark, B. A. et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2402309 (2024) - DOI - PubMed

[3] Stroes, E. S. G. et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2400201 (2024) - DOI - PubMed

[4] Stroes, E. S. G. et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2400201 (2024) - DOI - PubMed

[5] Gaudet, D. et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2024.0959 (2024) - DOI - PubMed

[6] Gaudet, D. et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2024.0959 (2024) - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia

Affiliation

RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia

Author

Affiliation

Comment on

Similar articles

Cited by

References

Original articles

Related article

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Comment on

Similar articles

Cited by

References

Original articles

Related article

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous